medigraphic.com
Instituto Nacional de Salud Pública

2018, Number 6

<< Back Next >>

salud publica mex 2018; 60 (6)

Realities of alternative HPV vaccination schedules

Stanley M

Language: English
References: 26
Page: 617-620
PDF size: 644.27 Kb.


Text Extraction

The ability to generate human papillomavirus (HPV) virus like particles (VLPs) by the synthesis and selfassembly in vitro of the major virus capsid protein L1 has transformed our prospects for preventing benign and malignant disease caused by HPV particularly the most prevalent HPV caused malignancy – cervical cancer in women. HPV L1 VLPs are structures geometrically and antigenically almost identical to the native virion but lack DNA and are therefore non-infectious. Three HPV L1 VLP prophylactic vaccines have been developed and are commercially available (figure 1); Cervarix, a bivalent HPV16/18 product (2vHPV) from GlaxoSmithKline Biologicals Rixensart Belgium, and Gardasil also known as Silgard, a quadrivalent HPV16/18/6/11 product (4vHPV) from MSD Merck, Whitehouse Station, New Jersey USA have been licensed since 2006/7 in the USA and Europe, Gardasil9 HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 a nonavalent product (9vHPV) licensed in 2014/15 in the USA and Europe.


REFERENCES

  1. Inglis S, Shaw A, Koenig S. Chapter 11: HPV vaccines: commercial research & development. Vaccine. 2006;24(Suppl 3):S3/99-105. https://doi. org/10.1016/j.vaccine.2006.05.119

  2. Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness Of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of Ten Years of Real-World Experience. Clin Infect Dis. 2016;63(4):519-27. https://doi.org/10.1093/cid/ciw354

  3. Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111(9):1824-30. https://doi.org/10.1038/bjc.2014.479

  4. Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017; 17(12):1293-302. https://doi.org/10.1016/S1473-3099(17)30468-1

  5. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. https://doi.org/10.1136/bmj.f2032

  6. Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population- level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-80. https://doi.org/10.1016/S1473-3099(14)71073-4

  7. World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241-68.

  8. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453-63. https://doi.org/10.1016/S2214-109X(16)30099-7

  9. Brotherton JML, Bloem PN. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Pract Res Clin Obstet Gynaecol. 2017;47:42- 58. https://doi.org/10.1016/j.bpobgyn.2017.08.010

  10. Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med. 2011;53(Suppl 1):S29-35. https://doi.org/10.1016/j.ypmed.2011.08.015

  11. Bloem P, Ogbuanu I. Vaccination to prevent human papillomavirus infections: From promise to practice. PLoS medicine. 2017;14(6):e1002325. https://doi.org/10.1371/journal.pmed.1002325

  12. Gilca V, Salmeron-Castro J, Sauvageau C, Ogilvie G, Landry M, Naus M, et al. Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact. Vaccine. 2018;36(32 Pt A):4800-5. https://doi.org/10.1016/j.vaccine.2018.02.004

  13. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135-45. https://doi.org/10.1542/peds.2006-0461

  14. Lazcano-Ponce E, Salmeron-Castro J, Garcia-Carranca A, Aranda-Flores C, Madrid-Marina V, Gomez-Altamirano CM, et al. Recomendaciones para la definición de la política de vacunación contra el virus del papiloma en México. Salud Publica Mex. 2009;51(4):336-41. https://doi.org/10.1590/ S0036-36342009000400011

  15. Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, et al. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine. Hum Vaccin Immunother. 2015;11(3):732-8. https://doi.org/10.1080/21645515.2015.1011570

  16. Lazcano-Ponce E, Stanley M, Munoz N, Torres L, Cruz-Valdez A, Salmeron J, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine. 2014;32(6):725-32. https://doi.org/10.1016/j.vaccine.2013.11.059

  17. Hernandez-Avila M, Torres-Ibarra L, Stanley M, Salmeron J, Cruz-Valdez A, Munoz N, et al. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother. 2016;12(1):30-8. https://doi.org/10.1080/21645515.2015.1058458

  18. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04- adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374-86. https://doi.org/10.4161/hv.7.12.18322

  19. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793-802. https://doi.org/10.1001/jama.2013.1625

  20. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 – conclusions and recommendations. Wkly Epidemiol Rec. 2014;89(21):221-36.

  21. Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, et al. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018;36(32 Pt A):4774-82. https://doi.org/10.1016/j.vaccine.2017.12.078

  22. Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, et al. Durability of protection afforded by fewer doses of the HPV16/18 Vaccine: The CVT Trial. J Natl Cancer Inst. 2018;110(2). https://doi.org/10.1093/ jnci/djx158

  23. Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17(1):67-77. https://doi.org/10.1016/ S1470-2045(15)00414-3

  24. Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018;36(32 Pt A):4783-91. https://doi.org/10.1016/j.vaccine.2018.02.087

  25. Scherer EM, Smith RA, Carter JJ, Wipf GC, Gallego DF, Stern M, et al. Analysis of memory B cell responses reveals suboptimal dosing schedule of a licensed vaccine. J Infect Dis. 2018;217(4):572-580. https://doi. org/10.1093/infdis/jix566

  26. Toh ZQ, Russell FM, Reyburn R, Fong J, Tuivaga E, Ratu T, et al. Sustained antibody responses 6 years following 1, 2, or 3 doses of quadrivalent Human Papillomavirus (HPV) vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: A prospective cohort study. Clin Infect Dis. 2017;64(7):852-9.




2020     |     www.medigraphic.com